TG Therapeutics reports positive Phase 1 subcutaneous BRIUMVI trial results

June 3, 2026 7:30 AM

TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found